* Fulgent Genetics Inc FLGT.OQ FLGT.O is expected
to show a
fall in quarterly revenue when it reports results on November
7.
* The Temple City California-based company is expected to
report
a 59.9% decrease in revenue to $91.36 million from $227.87
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. The company's guidance on
August 4 2022, for the period ended September 30, was for
revenue of $54.000 million.
* Refinitiv's mean analyst estimate for Fulgent Genetics
Inc is
for earnings of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $67.5, above its last closing price of $37.98.
This summary was machine generated November 5 at 03:05 GMT. All
figures in US dollars unless otherwise stated